- Home
- FUN vs JANX Comparison
FUN vs JANX Comparison
Compare FUN & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FUN | JANX |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 1987 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FUN | JANX |
|---|---|---|
| Price | $15.08 | $13.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $28.31 | ★ $60.27 |
| AVG Volume (30 Days) | ★ 2.9M | 2.6M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,137,510,000.00 | $10,000,000.00 |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.13 | N/A |
| 52 Week Low | $12.51 | $13.62 |
| 52 Week High | $49.77 | $61.59 |
Technical Indicators
Market Signals| Indicator | FUN | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 27.00 |
| Support Level | $13.00 | $13.82 |
| Resistance Level | $15.82 | $14.49 |
| Average True Range (ATR) | 0.67 | 0.49 |
| MACD | 0.25 | 0.28 |
| Stochastic Oscillator | 74.47 | 4.21 |
Price Performance
Historical ComparisonAbout FUN Cedar Fair L.P.
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.